A phase III, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC).

被引：0

作者：

Rischin, Danny

Fury, Matthew G.

Lowy, Israel

Stankevich, Elizabeth

Han, Hyunsil

Porceddu, Sandro

机构：

[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[2] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA

[3] Regeneron Pharmaceut Inc, Basking Ridge, NJ USA

[4] Univ Queensland, Sch Med, Herston, Qld, Australia

[5] Princess Alexandra Hosp, Dept Radiat Oncol, Woolloongabba, Qld, Australia

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS10084

引用

页数：1